A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer

Drug Safety

Volumn 34, Issue 3, 2011, Pages 175-186

  Mountzios, Giannis ^a   Syrigos, Kostas N ^b  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Benefit risk assessment; Epidermal growth factor receptor antagonists general; Erlotinib adverse reactions; Non small cell lung cancer; Pancreatic cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOPLASM PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; PLACEBO; SERINE; THREONINE; TYROSINE KINASE RECEPTOR;

ACNE; ANOREXIA; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CHEMORADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; ECZEMA; EVIDENCE BASED MEDICINE; FATIGUE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HEALTH CARE COST; HEART FAILURE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RASH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STOMATITIS; VOMITING; XEROSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT;

EID: 79951797044     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11586540-000000000-00000     Document Type: Review

References (58)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25: 5570-7
3. Subramanian J, Govindan R. Lung cance (Pubitemid 350002964)
4. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6 (Pubitemid 46972777)
6. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32 (Pubitemid 41058344)
7. Stepanski EJ, Houts AC, Schwartzberg LS, et al. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. Clin Lung Cancer 2009; 10: 426-32
8. Ailawadhi S, Derby L, Natarajan R, et al. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter? A single-institution experience. Oncology 2009; 76: 85-90
9. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009; 10: 28-35
10. Capdevila J, Elez E, Macarulla T, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009; 35: 354-63
11. Mountzios G, Dimopoulos MA, Soria JC, et al. Histo- pathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit Rev Oncol Hematol 2010; 75 (2): 94-109
12. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 2009; 14: 137-47
13. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57
14. De Luca A, Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 2010; II (7): 851-64
15. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009; 20 (10): 851-5
16. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and phar- macologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79 (Pubitemid 32591445)
17. Perez-Soler R, Chachoua A, Hammond LA, etal. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47 (Pubitemid 41103678)
18. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44 (Pubitemid 41058345)
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500 (Pubitemid 38720929)
20. Spanish Lung Cancer Group. Phase III study (Tarceva®) vs chemotherapy to treat advanced non-small cell lung cancer (NSCLC) in patients with mutations in the TK domain of EGFR [ClinicalTrials.gov identifier NCT00446225]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00446225 [Accessed 2010 Sep 9]
21. Hoffmann-La Roche. A study of first or second line treat- ment with Tarceva (erlotinib) in patients with advanced non-small cell lung cancer [ClinicalTrials.gov identifier NCT01066884]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov/ct2/show/NCT01066884?term=erlotinib+ AND+monotherapy& rank=12 [Accessed 2010 Sep 9]
22. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gem-citabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-52 (Pubitemid 46733081)
23. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-9
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50 (Pubitemid 44917502)
25. Cappuzzo F, Coudert B, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study [abstract no. A2.1]. 13th World Conference on Lung Cancer IASCL 2009; 2009 Jul 31-Aug 4; San Francisco (CA)
26. Milller V, O'Connor P, Soh CH, et al. A randomized, double blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy with bevacizumab for 1st-line treatment of locally-advanced, recurrent, or meta-static non-small cell lung cancer (NSCLC) [abstract no. LBA8002]. J Clin Oncol 2009; 27: 18s
27. Pennell NA, Lynch Jr TJ. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009; 14: 399-411
28. Herbst RS, Sandler A. Bevacizumab and erlotinib: a pro- mising new approach to the treatment of advanced NSCLC. Oncologist 2008; 13: 1166-76
29. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25: 4743-50 (Pubitemid 350086476)
30. Hainsworth J, Lin M, O'Connor P, et al. A phase III, multicenter, placebo-controlled, double-blind, randomized, clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer (NSCLC) after failure of standard first line chemotherapy (BETA). J Thorac Oncol 2008; 3 (Suppl. 4): S302
31. Wacker B, Nagrani T, Weinberg J, et al. Correlation be- tween development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Can Res 2007; 13: 3913-21 (Pubitemid 47037599)
32. Chou CL, Ko HW, Wang CW, et al. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. Chang Gung Med J 2010; 33: 100-5
33. Nishimura T, Tada H, Fukushima M. Lessons from gefiti- nib-induced interstitial lung disease: pharmacovigilance for erlotinib in Japan. Int J Risk Saf Med 2009; 21 (4): 237-8
34. Lee S, Rudd R, Khan I, et al. TOPICAL: randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy [abstract]. J Clin Oncol 2010; 28 (15 Suppl.): 7504
35. Lynch Jr TJ, Kim ES, Eaby B, et al. Epidermal growth fac- tor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-21 (Pubitemid 350012125)
36. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13 (Pubitemid 27251144)
37. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gem-citabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-5 (Pubitemid 34831525)
38. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-83 (Pubitemid 41095218)
39. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-16
40. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-45 (Pubitemid 41510138)
41. Abou-Alfa GK, Letourneau R, Harker G, et al. Random- ized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24: 4441-7 (Pubitemid 46630982)
42. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemci-tabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-8 (Pubitemid 41103625)
43. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemci-tabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-7
44. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926-35 (Pubitemid 30395817)
45. Ng SS, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, ondown-stream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002; 1: 777-83
46. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25: 4787-92 (Pubitemid 350086482)
47. Boeck S, Vehling-Kaiser U, Waldschmidt D, et al. Erlotinib 150mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsge- meinschaft Internistische Onkologie'. Anticancer Drugs 2010; 21: 94-100
48. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328-35 (Pubitemid 40524617)
49. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 2005; 28: 570-5 (Pubitemid 41790008)
50. Danson S, Blackhall F, Hulse P, et al. Interstitial lung dis- ease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005; 28: 103-13 (Pubitemid 40321766)
51. Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 2010; 28: 75-92
52. Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors: a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470-81
53. Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010; 102: 298-306
54. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in ad- vanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment Study. J Thorac Oncol 2010; 5 (10): 1616-22
55. Mok T, Wu YL, Au JS, et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5 (10): 1609-15
56. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007; 25: 4506-7 (Pubitemid 350013866)
57. Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 2007; 25: 1949-52 (Pubitemid 46972773)
58. Siena S, Sartore-Bianchi A, Di NF, et al. Biomarkers pre- dicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-24